Showing results (581-590 of 646) with videos related to
Sort By:
Pageof 65
The New England Journal of Medicine|January 17, 2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1Kris V Kowdley, Eric Lawitz, Fred Poordad, et al.Lancet (London, England)|October 13, 2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyDavid Roth, David R Nelson, Annette Bruchfeld, et al.Plos One|August 2, 2018
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational studyDonna M Evon, Paul W Stewart, Jipcy Amador, et al.The New England Journal of Medicine|September 16, 2011
Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman, Steven L Flamm, Nezam H Afdhal, et al.Journal of Hepatology|April 4, 2020
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohortElizabeth C Verna, Giuseppe Morelli, Norah A Terrault, et al.Nature Communications|October 13, 2023
Characterization of the horse chestnut genome reveals the evolution of aescin and aesculin biosynthesisWei Sun, Qinggang Yin, Huihua Wan, et al.Plos Genetics|February 5, 2019
Genomic insights into neonicotinoid sensitivity in the solitary bee Osmia bicornisKatherine Beadle, Kumar Saurabh Singh, Bartlomiej J Troczka, et al.Open Forum Infectious Diseases|August 28, 2025
Development and Validation of a Machine Learning-Based Screening Algorithm to Predict High-Risk Hepatitis C InfectionSuk-Chan Jang, Wei-Hsuan Lo-Ciganic, Pilar Hernandez-Con, et al.Journal of Hepatology|May 17, 2019
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP studyDonna M Evon, Souvik Sarkar, Jipcy Amador, et al.Gut|July 16, 2016
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET studyTania M Welzel, David R Nelson, Giuseppe Morelli, et al.Pageof 65